Search

Displaying results 4271 - 4280 of 4627 in total
  1. Drug

    Tunicamycin

    go.drugbank.com/drugs/DB13172
    Experimental

    Tunicamycin is produced by Streptomyces clavuligerus and Streptomyces lysosuperficus bacteria along with several other species.

  2. Drug

    EP-1043

    go.drugbank.com/drugs/DB06118
    Experimental

    The vaccine consists of a string of 18 HIV-derived major histocompatibility complex (MHC) Class II restricted epitopes, each separated by a spacer designed to optimize potency.

  3. Drug

    WX-UK1

    go.drugbank.com/drugs/DB05476
    Investigational

    In animal models, WX-UK1 blocks tumor cell invasion, metastasis and primary tumor growth by inhibiting serine proteases and the urokinase Plasminogen Activator (uPA) system, which have been shown to play

  4. Drug

    Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

    go.drugbank.com/drugs/DB16443
    Investigational

    The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853].

  5. Drug

    Tozorakimab

    go.drugbank.com/drugs/DB16473
    Investigational

    Tozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions.

  6. Drug

    MBO7133

    go.drugbank.com/drugs/DB04999
    Experimental

    MB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is used to treat leukemia but is ineffective against primary liver cancer.

  7. Drug

    Phenserine

    go.drugbank.com/drugs/DB04892
    Investigational

    Phenserine is under development by Axonyx, a US biopharmaceutical company that focuses on treatments for dementia.

  8. Drug

    OT-551

    go.drugbank.com/drugs/DB05650
    Investigational

    Age-related macular Degeneration (AMD), and preclinical research results indicate additional uses for OT-551, including treatment of early stage and advanced dry age-related macular degeneration (AMD) by

  9. Drug

    Inactivated SARS-Cov-2 Vaccine

    go.drugbank.com/drugs/DB15862
    Investigational

    Developed by Sinopharm's Wuhan Institute of Biological Products co., this vaccine consists of the WIV04 strain of SARS-CoV-2.

  10. Drug

    MVA-BN-brachyury-TRICOM vaccine

    go.drugbank.com/drugs/DB17424
    Investigational

    [L44513] MVA-BN-brachyury-TRICOM vaccine is administered as a priming vaccine, followed by the administration of the fowlpox virus(FPV)‐Brachyury booster vaccine.